Completed PHASE4 INTERVENTIONAL 1-arm NCT02944604

The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy

Sponsor: Peking University

Interventions PEG-rhG-CSF

Updated 7 times since 2017 Last updated: Jan 16, 2019 Started: Sep 8, 2016 Primary completion: Sep 29, 2017 Completion: Sep 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02944604, this PHASE4 trial focuses on Breastcancer and remains completed. Sponsored by Peking University, it has been updated 7 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Feb 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE4

▶ Show 2 earlier versions

Jan 2018 — Jun 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Jan 2018 [monthly]

Recruiting PHASE4

First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University

Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China